Entelos, Inc. Announces U.S. Patent for its Diabetes Model
This patent relates to the mathematical and computer modeling of multiple biological processes underlying the Entelos Metabolism PhysioLab platform. These processes include, for example, glucose regulation and the metabolism of protein, fat, and carbohydrates, as well as digestion, absorption, and storage. The effects of changes in physical activity and diet on such physiological processes can also be tested. In addition, the model can simulate a wide array of virtual diabetic patients, from insulin-resistant to severely diabetic subtypes, and can predict the likely effects of drugs and other treatment interventions.
The Entelos Metabolism platform, which can be applied to obesity as well as diabetes research, has already been used successfully with multiple pharmaceutical partners to select compounds to develop as treatments for diabetes, find the best doses for clinical trials, identify biomarkers, and characterize patient subtypes most responsive to certain drugs and drug combinations.
"This patent represents another milestone in Entelos' intellectual property strategy and strengthens the Company's leadership position in the quantitative modeling of human biology generally and diabetes in particular," stated John Rigsbee, General Counsel of Entelos. "Currently, we have 34 issued patents and over 120 pending applications worldwide directed to our software modeling technologies, the methodologies of applying our PhysioLab models to drug research and development, and the PhysioLab models themselves."
Diabetes is a disease in which the body does not produce or properly use insulin, a hormone that is needed to convert sugar, starches and other food into energy in the body. The cause of diabetes continues to be a mystery, although both genetics and environmental factors such as obesity and lack of exercise appear to play roles.
Untreated diabetes can lead to many serious long-term complications such a kidney failure, amputations, blindness, and life-threatening cardiovascular-related events such as heart attacks and stroke. Diabetes is one of the fastest growing epidemics in the developing world and is projected to rise from 84 million in 1995 to 228 million by the year 2025. “It is well known that a patient’s response to a drug depends on multiple factors, from underlying genetics to diet and lifestyle,” stated James Karis, President and CEO of Entelos. “Diabetes is even more complex, in that multiple drugs are often used to treat the disease over time. We are pleased to have this important model patent-protected to sustain our leadership position in the comprehensive in silico testing of multiple drugs and drug combinations in a highly variable virtual patient population. We intend to continue making a significant impact on this disease and on our customers’ diabetes-related programs.”
For further information please contact: Entelos, Inc. James Karis, President and CEO Jill Fujisaki, VP Investor Relations Tel: +1 650 572 5400 Buchanan Communications Lisa Baderoon / Mary-Jane Johnson Tel +44 (0) 20 7466 5000